GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Cash Conversion Cycle

PetIQ (PETQ) Cash Conversion Cycle : 66.17 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is PetIQ Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

PetIQ's Days Sales Outstanding for the three months ended in Mar. 2024 was 47.14.
PetIQ's Days Inventory for the three months ended in Mar. 2024 was 73.09.
PetIQ's Days Payable for the three months ended in Mar. 2024 was 54.06.
Therefore, PetIQ's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 66.17.


PetIQ Cash Conversion Cycle Historical Data

The historical data trend for PetIQ's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetIQ Cash Conversion Cycle Chart

PetIQ Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only 48.83 54.71 57.38 60.32 49.00

PetIQ Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.91 56.73 57.34 66.78 66.17

Competitive Comparison of PetIQ's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, PetIQ's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetIQ's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PetIQ's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where PetIQ's Cash Conversion Cycle falls into.



PetIQ Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

PetIQ's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=38.33+64.88-54.21
=49.00

PetIQ's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=47.14+73.09-54.06
=66.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetIQ  (NAS:PETQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


PetIQ Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of PetIQ's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


PetIQ (PETQ) Business Description

Traded in Other Exchanges
Address
230 East Riverside Drive, Eagle, ID, USA, 83616
PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.
Executives
William J. Carter officer: EVP, GENERAL COUNSEL C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson officer: EVP, Services & Manufactured C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman officer: General Counsel and Secretary 923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith officer: EVP - Products 923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff director 923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman officer: Chief Financial Officer C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis director C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen director, officer: Chief Executive Officer 500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland officer: Chief Financial Officer C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy director, 10 percent owner 500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p. 10 percent owner 437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022